TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01204996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection
Description: 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO888 + gemcitabine
Description: 15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO888 + Paclitaxel and carboplatin
Description: 15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO888 + docetaxel
Description: 15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
Study: NCT02136654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes program
Description: Includes family member and peer support Includes communication training
Study: NCT06509867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DGG+PRF
Description: de-epithelialized subepithelial connective tissue grafts+ L-Platelet Rich Fibrin + Coronally advanced flap

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DGG
Description: de-epithelialized subepithelial connective tissue grafts+ Coronally advanced flap
Study: NCT04541199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed loop
Description: RR and VT will be selected according to the respiratory mechanics by closed loop algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: RR, VT, Ti will be selected by the clinician according to the respiratory mechanics
Study: NCT01179100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
Study: NCT01833598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNT + PRP
Description: The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNT alone
Description: The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
Study: NCT02123953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-438 Placebo
Description: TAK-438 placebo-matching tablets
Study: NCT03392194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene intervention
Description: The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene intervention
Description: The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Description: Following the SH intervention, participants randomized to the SH+Y arm will participate in 8 weekly beginner level yoga classes. Classes will increase participants' skill and comfort with yoga postures and relaxing breathing exercises so that participants can adopt an evening yoga practice (10 weeks).
Study: NCT01453738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex- vivo cultured adult allogeneic MSCs
Description: Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasmalyte-A
Description: Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
Study: NCT00075387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IA
Study: NCT00431054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 by vein over 1 hour every 4 weeks
Study: NCT04009772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: Antibiotic prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime plus Metronidazole
Description: Antibiotic prophylaxis
Study: NCT03682614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Description: we will use the catheter to pass through the cervix, and after that, the experiment Group will accept 40 μl 500 IU HCG injection into the uterine cavity 2 days before the blastocyst transfer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: culture medium
Description: The placebo group will accept 40 μl of culture medium injection into the uterine cavity 2 days before the blastocyst transfer.
Study: NCT00075387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV
Study: NCT01363180

Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test (TSST)
Description: The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.

Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test (TSST)
Description: The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.

Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test (TSST)
Description: The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.

Intervention type: OTHER
Intervention: No stress condition

Intervention type: OTHER
Intervention: No stress condition

Intervention type: OTHER
Intervention: No stress condition
Study: NCT03424369

Intervention type: PROCEDURE
Intervention: Tympanoplasty
Description: Tympanoplasty
Study: NCT04648670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: The intervention was applied to the experimental group and consisted in 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises..
Study: NCT03838991

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: A study specific blood sample will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A study specific blood sample will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A study specific blood sample will be collected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waste bone tissue
Description: For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waste bone tissue
Description: For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waste bone tissue
Description: For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.
Study: NCT00881153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
Study: NCT02753621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group singing
Description: Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated Discussion Group
Description: Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
Study: NCT00867087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin (CMC-544)
Description: 1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
Study: NCT02654392

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn syrup
Description: This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Polyunsaturated fatty acid
Description: This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, \& Pumpkin oils) every day for 5 weeks
Study: NCT05164601

Intervention type: OTHER
Intervention: No Intervention - Observational Only
Description: Clinical Follow-Up
Study: NCT03197974

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness for Bipolar
Description: Brief online self-management program with email coaching support

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducation for Bipolar
Description: Brief online self-management program with email coaching support
Study: NCT02070393

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton
Description: 14-24 Radiation treatments using Protons
Study: NCT04053023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
Study: NCT01490476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10 mg per os / day or 05mg per os / day with 12 month
Study: NCT01899794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O/Oxytrol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O/Oxytrol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytrol
Study: NCT02834208

Intervention type: OTHER
Group type: OTHER
Intervention: MRI (Magnetic resonance imaging)

Intervention type: OTHER
Group type: OTHER
Intervention: MRI (Magnetic resonance imaging)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI (Magnetic resonance imaging)

Intervention type: GENETIC
Group type: OTHER
Intervention: Polymorphism (SNP in DNA)

Intervention type: GENETIC
Group type: OTHER
Intervention: Polymorphism (SNP in DNA)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polymorphism (SNP in DNA)
Study: NCT01755559

Intervention type: DRUG
Group type: OTHER
Intervention: Artesunate-amodiaquine
Description: antimalarial ACT

Intervention type: DRUG
Group type: OTHER
Intervention: Dihydroartemisinin-piperaquine
Description: antimalarial ACT
Study: NCT02258516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIME 3-M
Description: behavioral intervention for self-management in heart failure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention control
Description: patients will receive phone calls regarding health-related topics not associated with heart failure
Study: NCT01158885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine intravenous
Description: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) Cytarabine
Description: Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.~If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.~Dose should be given according to age as defined below:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age
Study: NCT01185613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy™ Cool Flex Ablation Catheter
Description: The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.~The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter~* IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.~* Cool Point™ Irrigation Pump~* Cool Point™ Tubing set~* Data Logger
Study: NCT03813576

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Self-collected HPV vaginal swab
Description: Patients will be instructed on how to collect a vaginal swab on themselves which will then be processed for presence of HPV DNA.
Study: NCT03436992

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Cocktail
Description: Vitamin C, Vitamin E, alpha lipoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Cocktail
Description: Vitamin C, Vitamin E, alpha lipoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 1500 mg trans-resveratrol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 1500 mg trans-resveratrol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT01678794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
Study: NCT03142724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-968
Description: Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
Study: NCT03871348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441000
Description: Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441000
Description: Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral
Study: NCT01157585

Intervention type: DRUG
Group type: OTHER
Intervention: paliperidone ER
Description: 8 week prospective study
Study: NCT01533285

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Salmonella typhi vaccine (Typhim Vi)
Description: Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Salmonella typhi vaccine (Typhim Vi)
Description: Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Salmonella typhi vaccine (Typhim Vi)
Description: Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
Study: NCT03871348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441000
Description: Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441000
Description: Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441000
Description: Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441000
Description: Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous
Study: NCT02785458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMC2 Strategy
Description: The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
Study: NCT02100163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Hypnosis
Description: The patient receives virtual reality hypnosis daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Hypnosis
Description: Patient will listen to an Audio Hypnosis recording daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Study: NCT03128268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging software for 4 dimensional images for Cardiac MRI
Description: All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI